The typical patient journey used to be fairly linear. For years, patients experienced symptoms, visited their doctor, and were prescribed treatment. Today, that model is quickly eroding. Patients can research symptoms, compare treatments, message AI chatbots about medication side effects, hear about other patients’ experiences on social media, look up medicine costs, and explore alternatives online before ever setting foot in a doctor’s office. Doctors are still very important. But doctors are quickly becoming far from the beginning of the treatment journey. There’s another thing pharmas can’t ignore: Price is becoming part of the treatment decision.
Patients Have Become Digital Health Researchers
The scale of online health behavior is substantial.
According to a 2026 KFF Tracking Poll, 68% of U.S. adults said they used an internet search engine for health information or advice in the past year. Even more striking, 32% reported turning to artificial intelligence tools for health information or advice.
AI is not being used solely to define unfamiliar medical terms. KFF found that:
- 27% of adults had used AI for physical-health questions involving symptoms or general information about a condition.
- 19% had used AI to explain medical tests, lab results, or diagnoses.
- 19% had used AI to understand and compare treatment options.
- 16% had used AI to help decide whether they should see a doctor or seek medical care.
That represents a fundamental change in patient behavior. Patients aren’t simply searching for information anymore.
Patients are using digital information to navigate decisions.
Social Media Has Entered the Treatment Journey Too
Search engines and AI aren’t the only sources shaping perceptions. KFF reported in June 2026 that 31% of adults use social media at least monthly for health information or advice, while 29% use AI tools or chatbots for health information at least monthly.
Earlier KFF research found that 55% of adults use social media for health information at least occasionally. Exposure is even greater: 72% reported seeing social-media content concerning weight loss, diet or nutrition during the previous month, while 58% had encountered mental-health content.
Why are people going there?
Part of the appeal is something traditional pharmaceutical communications have historically struggled to provide: the experiences of people like them.
KFF found that wanting to learn from people with the same health condition or similar experiences was an important reason people sought health information through social media. Among women who used social media for health information, 39% cited this as a major reason, as did 44% of adults ages 18-29.
That means the modern treatment decision can involve two very different forms of evidence. There is the clinical evidence presented by physicians, medical organizations, and pharma.
Then there is what might be called experiential evidence:
“I took this drug.”
“These were my side effects.”
“It worked for me.”
“My insurance wouldn’t cover it.”
“This is what I paid.”
For patients, both can influence perception.
But Patients Don’t Necessarily Verify What They Find
This is where the digital-health revolution becomes more complicated. People increasingly have access to enormous amounts of health information, but access should not be confused with accuracy.
KFF found that among adults using social media for health information, only 36% follow up with a physician at least most of the time, 35% check another online source such as WebMD and just 21% check a health agency website such as the CDC.
AI creates a similar issue.
Among people who used AI for physical-health advice, 58% subsequently followed up with a healthcare provider. That also means a substantial minority did not.
This creates a significant challenge for healthcare professionals and pharma companies. Patients may walk into an appointment having already developed opinions about:
- their diagnosis,
- which treatments they want,
- which drugs they don’t want,
- expected side effects,
- competing therapies,
- what other patients experienced,
- and what they believe the treatment should cost.
The clinical conversation increasingly starts after the consumer has done their own research.
Then Comes the Question That Can Override Everything: “How Much Will It Cost Me?”
A drug can have great efficacy. A doctor can feel it’s the best clinical option. A patient can agree to begin therapy. But that doesn’t ensure the medication will be purchased. Recent affordability stats are hard to overlook.
In March of 2026 the KFF reported that 43% of U.S. adults admitted they hadn’t taken their medication as prescribed in the prior year because of cost. That included: 31% taking an over-the-counter medication instead of filling a prescription. 27% not filling a prescription. 19% cutting pills in half or skipping doses.
Even more troubling, 43% who reported some kind of cost-related medication behavior had increased from approximately 31% three years previously. Medication affordability isn’t just a hypothetical issue that impacts society at large. Patients are changing their behavior because of cost.
The Impact Is Even Greater for Middle- and Lower-Income Patients
Cost-related nonadherence varies dramatically by household income. KFF found that 52% of adults with household incomes below $40,000 reported not taking medications as prescribed because of cost. Among households earning between $40,000 and $90,000, the figure was 47%.
Even among households earning $90,000 or more, approximately 30% reported cost-related medication behavior. This is important because pharmaceutical marketers sometimes implicitly segment patients into those who “can afford” therapy and those who cannot.
The data suggest affordability concerns reach well into the middle class.
Consumers Are Becoming Prescription-Price Shoppers
The Internet has also given patients something they never had before: significantly more price transparency. Patients can research what a drug costs before — or after — the doctor writes the prescription.
KFF’s March 2006 poll showed that in the past 12 months: 35% of adults had researched prescription prices online to find the lowest price. 36% had used a discount card or coupon to save money on a prescription. 16% had bought a less expensive prescription from an online pharmacy without insurance. 8% had bought a prescription directly from a drug company’s website.
Think about what those statistics represent.
The prescription transaction is starting to become like other retail purchases for millions of patients. They shop around. They compare prices. They look for discounts. They explore alternative sources. And they may even begin to question whether insurance is the least expensive way to fill the prescription.
Insurance Coverage Doesn’t Necessarily Solve the Problem
Even insured patients encounter substantial friction.
GoodRx Research reported that the average commercial insurance plan did not cover approximately 21% of medications, while 35% of medications that were covered carried restrictions such as prior authorization.
KFF provides another indication of the problem.
Among insured adults, 33% reported having an insurer deny coverage for a service, treatment or medication prescribed by their doctor during the previous two years.
Another 29% experienced delays, and 29% reported being required to try a lower-cost treatment before the insurer would cover the treatment initially recommended. Among patients with chronic conditions, these barriers were even more prevalent.
The implication for pharma is significant:
A prescription is not the same thing as a patient.
The commercial journey does not end when the physician writes the prescription. It ends when the patient obtains the medication, starts therapy, and remains on treatment.
Price Has Become Part of Clinical Decision-Making
The pharma industry has long drawn a distinction between clinical value and market access. Patients usually don’t. Patients essentially ask a series of questions all at once: Will it work? What are the side effects? What have other patients experienced? Does my doctor think I should take it? Will my insurance cover it? How much will I end up paying? Is there a less expensive alternative? And now: Can I find it cheaper online? That last series of questions can trump the first series. If a patient cannot afford a therapy, that therapy has very little real-world effectiveness if the patient never begins it or stops too soon.
Digital Health and Affordability Are Becoming Interconnected
One of the most interesting developments is that patients aren’t necessarily going online merely because it is convenient. Some are doing it because healthcare itself is difficult or expensive to access.
KFF found that roughly one in five AI health-information users cited problems accessing or affording healthcare as major reasons for turning to AI. Similar affordability and access motivations are evident among people seeking health information through social media.
That creates a feedback loop:
Higher healthcare costs → more online health research → greater treatment comparison → greater price transparency → more consumer pressure on treatment choices.
Digital health behavior and healthcare affordability therefore shouldn’t be viewed as separate trends. They are increasingly part of the same consumer journey.
Pharma Needs to Rethink the Patient Journey
The conventional pharmaceutical commercial model often places enormous emphasis on generating awareness and convincing physicians of a product’s clinical value. Those remain essential. But the modern journey looks more like this:
Symptoms → Google/AI → social media/patient experiences → physician → treatment options → insurance coverage → online price search → affordability decision → prescription fill → adherence
Every arrow represents an opportunity for the patient to change direction.
That means pharmaceutical launch planning needs to expand beyond the traditional question:
“How do we convince physicians to prescribe our drug?”
Companies also need to ask:
“What happens when the patient Googles our drug?”
“What does AI tell the patient about our drug versus competitors?”
“What are patients saying about it online?”
“Can patients easily determine what they’ll pay?”
“What happens when insurance rejects the prescription?”
“How quickly can patients find financial assistance?”
And perhaps most importantly:
“Does the patient believe the clinical benefit is worth the out-of-pocket cost?”
The Bigger Strategic Issue
The internet has not made physicians obsolete in health care decision-making. Quite the contrary.
Providers remain the most ubiquitous source of health information; one study by KFF found that 80% of adults had accessed health information or advice from a health care professional in the prior year.
However, physicians today practice medicine inside of a much larger information universe. Patients research before office visits, confirm—or dispute—prescriptions received afterward, and, importantly, vet price before starting treatment. For pharma, clinical differentiation may no longer be enough. Successful therapies increasingly depend on 4 things.
Clinical value + trust + access + affordability.
Take away any one piece and the patient journey falls short. Consider the most basic statistic of all– 43% of American adults have experienced some form of cost-related medication nonadherence. If almost half of your market is changing their medication behavior because of cost concerns, affordability is not just a market access problem. It’s a treatment decision problem. And for pharmaceutical companies that continue to silo pricing, digital health information, and patient decision-making into separate teams, you may be building commercial strategies around a patient journey that no longer exists.
